Elexacaftor negative in bacterial and mammalian in vitro assays and an in vivo chromosomal damage assay
“Elexacaftor was not genotoxic in a bacterial and a mammalian in vitro assay in the presence or absence of S9 metabolizing mix. Elexacaftor was also not genotoxic in a chromosomal aberration assay in vivo.”
Elexacaftor 6-month Tg.rasH2 mouse and 2-year rat: no tumorigenicity
“A 6-month study in Tg.rasH2 transgenic mice showed no evidence of tumorigenicity at 50 mg/kg/day dose, the highest dose tested. A two-year study was conducted in rats to assess the carcinogenic potential of elexacaftor. No evidence of tumorigenicity was observed in rats at elexacaftor oral doses up to 10 mg/kg/day”
Elexacaftor rat fertility: lower fertility, copulation and conception indices at high doses (NOAEL 55/25 mg/kg/day M/F)
“In conclusion, the NOAEL for reproductive toxicity was determined to be 55 mg/kg/day in males and 25 mg/kg/day in females based on lower male and female fertility, male copulation, and female conception indices at 75 mg/kg/day (males) and 35 mg/kg/day (females).”
✓ VerifiedFDA multi-discipline review, p. 50Source ↗
Safety pharmacology
Elexacaftor: no changes in temperature, blood pressure, heart rate or ECG in telemetered dogs (single dose up to 30 mg/kg nominal, 24.78 mg/kg measured)
“Effects of elexacaftor on the cardiovascular system were assessed in telemetered dogs. A single dose of elexacaftor up to a nominal dose of 30 mg/kg (24.78 mg/kg actually measured) did not result in any changes in body temperature, blood pressure, pulse pressure, heart rate, or ECGs.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative